Short answer
Tarsus Pharmaceuticals, Inc. (TARS) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $174M (up 69.4% year over year) with net income of −$19M.
Q2 2026 key financials · XBRL
- Revenue
- $174M
- +69.4% YoY · +7.3% QoQ
- Net income
- −$19M
- +8.8% YoY · −166.3% QoQ
- Operating margin
- -11.4%
- EPS (diluted)
- −$0.43
- +8.5% YoY · −168.8% QoQ
Source: XBRL data from the Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 10-Q on SEC EDGAR. USD.
Tarsus Pharmaceuticals, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- XDEMVY net product sales $173.9M, up more than 69% YoY in Q2 2026
- Net loss $18.6M vs $20.3M YoY for Q2 2026
- ECPs prescribing XDEMVY five or more times weekly doubled YoY
- Operating expenses expected to increase significantly with commercialization and pipeline advancement
- PIPE transaction expected to generate $125.0M gross proceeds on August 7, 2026
Risk Factors
- Newly added tariff risk triggered by 2026 trade actions, including tariffs up to 100% ad valorem under Section 232
- Regulatory compliance exposure from misconduct allegations, including potential exclusion from Medicare and Medicaid programs
- Cybersecurity risk from AI-enabled attacks compromising clinical data or personal information under CCPA
- Commercial risk from XDEMVY dependence as the company’s single FDA-approved product
- Financial risk from continued losses, including $25.5 million net loss and $452.1 million accumulated deficit through June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tarsus Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.